RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.